(NewsDirect)
By Ernest Dela Aglanu, Benzinga
Read the latestreport on NanoViricides, Inc (NYSE : NNVC) here .
The Centers for DiseaseControl (CDC) remains vigilant against the increased spread or returnof COVID because there are still closeto 20,000 hospitalizations with asmany as 2,300 deaths weekly directly from COVID infections inthe USA as of March 5, 2023.
Yet, effective treatments for COVID still remainelusive. Even so-called “ hybridimmunity ,” a combination of immunity derived from vaccinesand from natural infections, offers full or partial protection againstreinfection only for around eight months. All the antibodies that weredeveloped to fight the virus are essentially useless by now as thevirus keeps on changing its cloak. Therefore, the world continues toneed an effective treatment for COVID.
However, exciting news exists in that there isa company, NanoViricides Inc. (NYSE: NNVC), that has rapidlydeveloped a novel drug against COVID and most coronaviruses.
Significant problemswith the remaining antivirals currently on the market for COVID areknown: Molnupiravir (Merck, MRK), a pill that prevents replication ofthe viral RNA genome, is potentially mutagenic ,which can bring the risk of cancer and other diseases; Paxlovid(Pfizer, PFZ), an oral COVID antiviral, shows littleeffect on patients under 65 and the World Health Organizationhas recommendations against the use of Remdesivir (Gilead, GILD), a treatment only available intravenously and only forhospitalized patients.
Meanwhile, COVID is not gone. Rather, it is now everywhere,with the potential of breaking out into severe pandemics every fewyears.
Therefore,developing effective antivirals remains the only viable long-termstrategy against COVID. Antivirals help the patient recover, help theimmune system prevent the disease from causing serious harm, andimportantly, effective antivirals also stop the virus fromspreading.
Focus: There is a Company Developing A Broad-SpectrumAntiviral To Combat The Many COVID Variants And Most OtherCoronaviruses.
NanoViricides, a leading nano-pharmaceutical drug developmentand commercialization company, is directly addressing this veryimportant unmet need in healthcare. The company has rapidly developeda novel drug that works against most coronaviruses includingSARS-CoV-2.
NanoViricides is now getting ready to start clinical trialsoutside the US for its lead clinical drug candidate, NV-CoV-2, anantiviral to treat almost all important human coronaviruses. Thesecoronaviruses include SARS-CoV-2 and its variants which cause COVID,the seasonal coronaviruses that cause common colds such as OC-43,H229E, including the more severe ones that cause acute respiratorysyndromes similar to COVID like NL63, and also the deadly ones likeSARS-CoV-1 and MERS.
These coronaviruses are important because while SARS-CoV-2became a major pandemic, other endemic coronaviruses have been causingloss of productivity, human suffering, and deaths every year, alongwith causing minor epidemics with different types erupting around theglobe. And all of these viruses have the potential to generatevariants that canresult in major pandemics.
There are four known currently circulating globallyendemic human coronaviruses, namely, hCoV-229E, hCoV-OC43, hCoV-HKU1,and hCoV-NL63. Of these, NL63 causes symptoms similar to the DeltaSARS-CoV-2, with lower-lung disease and breathlessness, but with lessseverity and lower fatality rates. In addition ,the deadly SARS-CoV-1 caused a small global epidemic around 2002-2004;and the even more deadly MERS, which survives in camels, continues tobe a threat for travelers and residents of Middle Eastern countries.SARS-CoV-1 is presumed to be extinct because of its overall high casefatality rate of around 10%. MERS is sporadic because it has a verypoor ability for human-to-human transmission, but its case fatalityrate is approximately 35%, rivaling Ebola and Marburg viruses.
NanoViricides, Inc saysNV-CoV-2 is a “broad-spectrum” drug, which means that no matterhow much the coronavirus changes, this drug will continue to beeffective. The Company believes this drug will be substantially more effective than other therapiesand treatments already on the market. Also, it believes that NV-CoV-2can be added to other therapy regimens to achieve greatereffectiveness because it works by a mechanism different from that ofthe other available COVID drugs.
The Company has three formulations of the NV-CoV-2drug – as oral gummies, oral syrup, and as a solution for injection,infusion, and inhalation. These multiple formulations make the drugapplicable to a wide range of patients: both with or withoutcomorbidities; to out-patients with mild to moderate COVID infection;as well as to severe hospitalized cases.
NanoViricides is excited to move forward withits potential treatment for COVID and help facilitate the healthcareindustry’s efforts to deal with the ever-existing threat ofcoronavirus pandemics and to serve the market for COVID therapies andtreatments which is currently worth more than $11 billion globally.
Interested in learning more about NanoViricides,Inc (NYSE: NNVC) Visit itswebsite .
This article wasoriginally published on Benzinga here .
AboutNanoViricides
NanoViricides, Inc. (the "Company")(www.nanoviricides.com) is a development stage company that iscreating special purpose nanomaterials for antiviral therapy. TheCompany's novel nanoviricide® class of drug candidates aredesigned to specifically attack enveloped virus particles and todismantle them. Our lead drug candidate is NV-HHV-101 with its firstindication as dermal topical cream for the treatment of shingles rash.In addition, we are developing a clinical candidate for the treatmentof COVID-19 disease caused by SARS-CoV-2 coronavirus. The Companycannot project an exact date for filing an IND for this drug becauseof its dependence on a number of external collaborators andconsultants.The Company is now working on tasks for completing an INDapplication. The Company is currently pursuing two separate drugcandidates for the treatment of COVID-19 patients. NV-CoV-2 is ournanoviricide drug candidate that does not encapsulate Remdesivir.NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2with Remdesivir encapsulated in it. The Company believes that sinceRemdesivir is already US FDA approved, our drug candidateencapsulating Remdesivir is likely to be an approvable drug, if safetyis comparable. Remdesivir is developed by Gilead. The Company hasdeveloped both of its own drug candidates NV-CoV-2 and NV-CoV-2-Rindependently.The Company intends to re-engage into an IND applicationto the US FDA for NV-HHV-101 drug candidate for the treatment ofshingles once its COVID-19 project moves into clinical trials, basedon resources availability. The NV-HHV-101 program was slowed downbecause of the effects of recent COVID-19 restrictions, andre-prioritization for COVID-19 drug development work.The Company isalso developing drugs against a number of viral diseases includingoral and genital Herpes, viral diseases of the eye including EKC andherpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza,HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.NanoViricides' platform technology and programs are based on theTheraCour® nanomedicine technology of TheraCour, which TheraCourlicenses from AllExcel. NanoViricides holds a worldwide exclusiveperpetual license to this technology for several drugs with specifictargeting mechanisms in perpetuity for the treatment of the followinghuman viral diseases: Human Immunodeficiency Virus (HIV/AIDS),Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, HerpesSimplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV),Influenza and Asian Bird Flu Virus, Dengue viruses, JapaneseEncephalitis virus, West Nile Virus, Ebola/Marburg viruses, andcertain Coronaviruses. The Company intends to obtain a license forpoxviruses if the initial research is successful. The Company'stechnology is based on broad, exclusive, sub-licensable, fieldlicenses to drugs developed in these areas from TheraCour Pharma, Inc.The Company's business model is based on licensing technology fromTheraCour Pharma Inc. for specific application verticals of specificviruses, as established at its foundation in 2005.
Thispost contains sponsored advertising content. This content is forinformational purposes only and not intended to be investingadvice.
Contact Details
NanoViricides,Inc.
+1 203-937-6137
CompanyWebsite
Copyright (c) 2023 TheNewswire - All rights reserved.